Strattera is a selective norepinephrine reuptake inhibitor medicine. It is used for the treatment of attention deficit and hyperactivity disorder (ADHD). Strattera may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.
Strattera should be used as a part of a total treatment program for ADHD that may include counseling or other therapies.
Strattera has not been studied in children less than 6 years old.
Full therapeutic effects of Strattera may take at least a week to be felt. Strattera was originally intended to be a new antidepressant drug; however, in clinical trials, no such benefits could be proven. Since norepinephrine is believed to play a role in ADHD, Strattera was tested – and subsequently approved – as an ADHD treatment.